Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of PMN is 100 and suggests 1001% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell